We use essential cookies and third-party cookies for content.

Arizona Tribune - enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Arizona Tribune
×
NYSE - LSE
RBGPF -1.15% 68.56 $
CMSC -0.84% 21.102 $
BCC 0.85% 82.47 $
VOD -0.31% 15.96 $
BCE -0.3% 23.71 $
RELX 1.48% 35.91 $
RYCEF -0.84% 20.25 $
RIO 2.97% 105.3 $
BTI -0.87% 56.21 $
GSK 0.86% 52.41 $
NGG -1.08% 79.76 $
JRI -0.24% 12.38 $
CMSD -0.67% 20.98 $
BP -0.85% 44.76 $
AZN 0.9% 165.98 $
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

TECHNOLOGY 26.09.2025

Watch the "What This Means" video here

Text size:

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.

As part of the segment, Mr. Berman discussed the Company's recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).

The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of severe deep Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company is currently performing the final testing necessary to seek IDE approval from the FDA to begin the U.S. pivotal trial for enVVe.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198

SOURCE: enVVeno Medical Corporation



View the original press release on ACCESS Newswire

T.Perez--AT

Featured

Estimating Edge Releases New Article on Time Tracking's Role in Estimating Accuracy

Estimating Edge Releases New Article on Time Tracking's Role in Estimating Accuracy
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission 

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission 
Rain Enhancement Technologies Recognized With 2026 "AgTech Climate Innovation of the Year" by AgTech Breakthrough

Rain Enhancement Technologies Recognized With 2026 "AgTech Climate Innovation of the Year" by AgTech Breakthrough
Aureus Greenway Holdings Inc. and and Powerus Announce $22.3 Million Commercial Contract to Protect Critical Energy Infrastructure in the Middle East

Aureus Greenway Holdings Inc. and and Powerus Announce $22.3 Million Commercial Contract to Protect Critical Energy Infrastructure in the Middle East